ID

13529

Description

Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115); ODM derived from: https://clinicaltrials.gov/show/NCT01026870

Link

https://clinicaltrials.gov/show/NCT01026870

Keywords

  1. 2/13/16 2/13/16 -
Uploaded on

February 13, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Asthma NCT01026870

Eligibility Asthma NCT01026870

  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT01026870
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
an adult or adolescent subject with a diagnosis of persistent asthma of >=6 months duration may be selected for this study.
Description

adolescent; persistent asthma

Data type

boolean

Alias
UMLS CUI [1]
C0205653
UMLS CUI [2]
C3266628
both subject (and/or parent/guardian, if appropriate) and investigator must agree that changing therapy is acceptable and poses no inherent risk.
Description

Therapy change

Data type

boolean

Alias
UMLS CUI [1]
C3665894
subject must have been using a low daily maintenance dose of inhaled corticosteroids (ics), with or without added long-acting β2-agonist (laba), for >=12 weeks prior to screening, and must have been on a stable regimen (daily dose unchanged) for at least the last 2 weeks of that period.
Description

inhaled corticosteroids; Adrenergic beta-2 Receptor Agonists; regimen

Data type

boolean

Alias
UMLS CUI [1]
C3248292
UMLS CUI [2]
C2936789
UMLS CUI [3]
C0040808
at screening, the subject must have a prebronchodilator fev1 between 60% and 90% of the predicted value when restricted medications have been withheld.
Description

prebronchodilator fev1

Data type

boolean

Alias
UMLS CUI [1]
C1276012
to be randomized, the subjects must be symptomatic with fev1 at baseline must be between 50% and 85% of predicted.
Description

fev1

Data type

boolean

Alias
UMLS CUI [1]
C0802965
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
a subject must not have been admitted to the hospital for management of airway obstruction within the last 3 months prior to screening, and must not have experienced an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication, as judged by the clinical investigator at any time from screening to baseline/randomization.
Description

Airway Management; Airway Obstruction; Hospitalization

Data type

boolean

Alias
UMLS CUI [1]
C0150126
UMLS CUI [2]
C0001883
UMLS CUI [3]
C0019993
in addition, a subject must not have demonstrated a decrease in absolute fev1 of >20% at any time from screening to baseline, or a decrease in am peak expiratory flow (pef) below the pef stability limit on any 2 consecutive days prior to baseline/randomization.
Description

peak expiratory flow

Data type

boolean

Alias
UMLS CUI [1]
C0030735

Similar models

Eligibility Asthma NCT01026870

  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT01026870
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
adolescent; persistent asthma
Item
an adult or adolescent subject with a diagnosis of persistent asthma of >=6 months duration may be selected for this study.
boolean
C0205653 (UMLS CUI [1])
C3266628 (UMLS CUI [2])
Therapy change
Item
both subject (and/or parent/guardian, if appropriate) and investigator must agree that changing therapy is acceptable and poses no inherent risk.
boolean
C3665894 (UMLS CUI [1])
inhaled corticosteroids; Adrenergic beta-2 Receptor Agonists; regimen
Item
subject must have been using a low daily maintenance dose of inhaled corticosteroids (ics), with or without added long-acting β2-agonist (laba), for >=12 weeks prior to screening, and must have been on a stable regimen (daily dose unchanged) for at least the last 2 weeks of that period.
boolean
C3248292 (UMLS CUI [1])
C2936789 (UMLS CUI [2])
C0040808 (UMLS CUI [3])
prebronchodilator fev1
Item
at screening, the subject must have a prebronchodilator fev1 between 60% and 90% of the predicted value when restricted medications have been withheld.
boolean
C1276012 (UMLS CUI [1])
fev1
Item
to be randomized, the subjects must be symptomatic with fev1 at baseline must be between 50% and 85% of predicted.
boolean
C0802965 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Airway Management; Airway Obstruction; Hospitalization
Item
a subject must not have been admitted to the hospital for management of airway obstruction within the last 3 months prior to screening, and must not have experienced an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication, as judged by the clinical investigator at any time from screening to baseline/randomization.
boolean
C0150126 (UMLS CUI [1])
C0001883 (UMLS CUI [2])
C0019993 (UMLS CUI [3])
peak expiratory flow
Item
in addition, a subject must not have demonstrated a decrease in absolute fev1 of >20% at any time from screening to baseline, or a decrease in am peak expiratory flow (pef) below the pef stability limit on any 2 consecutive days prior to baseline/randomization.
boolean
C0030735 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial